Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0056 in Idiopathic Pulmonary Fibrosis
NCT07909655Phase 2Not yet recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HB0056 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Forced Vital Capacity at 24 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
HB0056
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07909655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909655.